Oppenheimer set a $9.00 price objective on Evofem Biosciences (NASDAQ:EVFM) in a report released on Wednesday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

Other equities analysts have also recently issued reports about the stock. HC Wainwright reissued a buy rating and issued a $11.00 price objective on shares of Evofem Biosciences in a research note on Wednesday, August 29th. Cantor Fitzgerald set a $9.00 price objective on shares of Evofem Biosciences and gave the stock a buy rating in a research note on Wednesday. Finally, ValuEngine raised shares of Evofem Biosciences from a hold rating to a buy rating in a research note on Thursday, November 1st. Six investment analysts have rated the stock with a buy rating, The stock has a consensus rating of Buy and an average price target of $10.40.

Shares of NASDAQ:EVFM traded down $0.10 on Wednesday, reaching $3.40. The company’s stock had a trading volume of 29,340 shares, compared to its average volume of 36,745. Evofem Biosciences has a 52-week low of $1.79 and a 52-week high of $12.90.

Evofem Biosciences (NASDAQ:EVFM) last issued its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.34). As a group, research analysts expect that Evofem Biosciences will post -5.32 EPS for the current fiscal year.

In other Evofem Biosciences news, Director Thomas G. Lynch acquired 100,000 shares of the company’s stock in a transaction on Wednesday, August 15th. The stock was acquired at an average cost of $2.26 per share, with a total value of $226,000.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders acquired a total of 108,000 shares of company stock valued at $243,770 over the last three months. Corporate insiders own 3.40% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Heartland Advisors Inc. bought a new stake in shares of Evofem Biosciences in the 3rd quarter worth about $1,319,000. Millennium Management LLC lifted its holdings in shares of Evofem Biosciences by 6,497.4% in the 2nd quarter. Millennium Management LLC now owns 733,765 shares of the biotechnology company’s stock worth $1,989,000 after acquiring an additional 722,643 shares during the last quarter. Finally, Woodford Investment Management Ltd lifted its holdings in shares of Evofem Biosciences by 28.5% in the 2nd quarter. Woodford Investment Management Ltd now owns 9,593,197 shares of the biotechnology company’s stock worth $25,998,000 after acquiring an additional 2,127,659 shares during the last quarter. Hedge funds and other institutional investors own 79.29% of the company’s stock.

About Evofem Biosciences

Evofem Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women.

Further Reading: How Do Tariffs Affect Trade Balances?

Analyst Recommendations for Evofem Biosciences (NASDAQ:EVFM)

Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.